Evidence map›Paper›PMID 27841858›Full record

Trial reportBone marrow transplantation2017

Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients.

R Oostvogels, E Kneppers, M C Minnema, R C Doorn, L E Franssen, T Aarts, M E Emmelot, E Spierings, I Slaper-Cortenbach, K Westinga and 3 more

Open access · greenAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Immunotherapy in myeloma: how far have we come?Therapeutic advances in hematology · 2019
    Review
  15. Review
  16. Graft versus tumor effects and why people relapse.Hematology. American Society of Hematology. Education Program · 2017
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

R OostvogelsDepartment of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
E KneppersDepartment of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
M C MinnemaDepartment of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
R C DoornDepartment of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
L E FranssenDepartment of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
T AartsDepartment of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
M E EmmelotDepartment of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
E SpieringsDepartment of Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
I Slaper-CortenbachDepartment of Clinical Pharmacy, Cell Therapy Facility, University Medical Center Utrecht, Utrecht, The Netherlands.
K WestingaDepartment of Clinical Pharmacy, Cell Therapy Facility, University Medical Center Utrecht, Utrecht, The Netherlands.
E GoulmyDepartment of Immunohematology and Blood bank, Leiden University Medical Center, Leiden, The Netherlands.
H M LokhorstDepartment of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
T MutisDepartment of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
University Medical Center Utrecht · NLAmsterdam UMC Location VUmc · NLLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Donor lymphocyte infusions (DLI) can induce durable remissions in multiple myeloma (MM) patients, but this occurs rather infrequently. As the graft-versus-tumor (GvT) effect of DLI depends on the presence of host-dendritic cells (DCs), we tested in a phase I/II trial whether the efficacy of DLI could be improved by simultaneous vaccination with host-DCs. We also analyzed the possibility of further improving the GvT effect by loading the DCs with peptides of mismatched hematopoietic cell-specific minor histocompatibility antigens (mHags). Fifteen MM patients not responding to a first DLI were included. Eleven patients could be treated with a second equivalent dose DLI combined with DC vaccinations, generated from host monocytes (moDC). For four patients, the DC products did not meet the quality criteria. In four of the treated patients the DCs were loaded with host mHag peptides. Toxicity was limited and no acute GvHD occurred. Most patients developed objective anti-host T-cell responses and in one patient a distinct mHag-specific T-cell response accompanied a temporary clinical response. These findings confirm that DLI combined with host-DC vaccination, either unloaded or loaded with mHag peptides, is feasible, safe and capable of inducing host-specific T-cell responses. The limited clinical effects may be improved by developing more immunogenic DC products or by combining this therapy with immune potentiating modalities like checkpoint inhibitors.

Indexed as

Antigens, NeoplasmLymphocyte TransfusionMinor Histocompatibility AntigensVaccinationDendritic CellsFemaleHumansMaleMultiple MyelomaAntigens, NeoplasmMinor Histocompatibility Antigens

Identifiers

PMID27841858
OpenAlexW2555998070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.